Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OCTAVE study of ranibizumab retreatment strategies in neovascular age-related macular degeneration
NL-OMON38832Phase 3Active, not recruiting
- Sponsor
- Novartis
- Start
- Sep 2013
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ranibizumab in exudative macular degeneration (2 arms), sponsored by Novartis. Primary endpoint: Average stable maximum best-corrected visual acuity change from Month 4 to Month 12 compared with Month 3. Started Sep 2013; status: active, not recruiting.
02
Drugs
ranibizumab
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on NL-OMON38832.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON38832.